ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings C

ACADIA Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $0.28 EPS, expectations were $0.32. ACADIA Pharmaceuticals Inc.

Related Keywords

United States , Japan , Toronto , Ontario , Canada , United Kingdom , American , Japanese , Mark Schneyer , Parag Meswani , Charles Duncan , Tessa Romero , Joel Beatty , Al Kildani , Steve Davis , Doug Williamson , David Hoang , Brendan Teehan , Gregory Renza , Ashwani Verma , Corporate Communications , American Epilepsy Society , Trial Court Level , Pharmaceuticals Inc , Pharmaceuticals Fourth Quarter , European Medicines Agency , Toronto Court Level , Japanese Regulatory Agency , Head Of Research , Rett Centers Of Excellence , Trial Court , Morgan Stanley , Acadia Pharmaceuticals Inc , Nasdaq , Rett Community , Call Transcript February , Fourth Quarter , Full Year , Results Conference , Senior Vice President , Investor Relations , Chief Executive Officer , Chief Operating Officer , Chief Financial Officer , Rare Disease Franchise , Private Securities Litigation Reform Act , Rett Centers , Inflation Reduction , Medicare Part D , Easiest Languages , English Speakers , Wall Street , Yash Verma , Ritu Baral , Jeff Hung , Ami Fadia , Markman Ruling ,